Clinical trials have compared Jesduvroq to intravenous epoetin alfa in those on hemodialysis (n=1 316, 88.5%), and subcutaneous darbepoetin alfa in those on peritoneal dialysis (n=171, 11%). The trials determined that Jesduvroq was non-inferior to these standard treatments with respect to the average change in hemoglobin levels. This essentially means it has the same effect as these other treatments.
Jesduvroq is used to raise hemoglobin levels and treat anemia associated with chronic kidney disease. It has not been proven to improve quality of life, tiredness (fatigue), or well-being.